News & Views
Latest News & Views
News & Views
Iksuda receives US FDA IND clearance for IKS04
CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’, is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
Iksuda receives US FDA IND clearance for IKS04
CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’, is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
Sign up for more news
Thank you